December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Most viewed in the last 7 days from JAMA Oncology
Apr 3, 2024, 06:05

Most viewed in the last 7 days from JAMA Oncology

JAMA Oncology shared a post on LinkedIn:

“Most viewed in the last 7 days from JAMA Oncology: Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemo immunotherapy?”

Additional information.
Source: JAMA Oncology/LinkedIn